India's Ranbaxy recalls gabapentin tablets in U.S.

MUMBAI, Nov 16 (Reuters) - Indian drugmaker Ranbaxy Laboratories Ltd (RANB.BO: Quote, Profile, Research, Stock Buzz) is recalling some gabapentin tablets in the United States, a spokesman said, confirming a report in the Economic Times on Friday.

"Ranbaxy is carrying out a voluntary recall of all lots of its 600mg and 800mg gabapentin tablets at the retail level as it found the presence of related substances permitted in the products to be outside the approved limit," the spokesman said.

He gave no other details about the recall for the generic drug used in treating nerve pain.

The newspaper said the recall involved 73 million tablets from the U.S. retail market, adding that Ranbaxy had a 2 percent share of the market for the specified dosages of the drug and the revenue impact was "not expected to be substantial". (Reporting by Rina Chandran; Editing by Ranjit Gangadharan)